Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-21
    E.g., 2018-02-21


19177 items
2:30 PM, Feb 02, 2018  |  BioCentury | Product Development

AA Viral meme

Gene therapy pioneer James Wilson’s revelation of two new types of toxicity in animals receiving high systemic doses of adeno-associated viral vectors is unlikely to herald a major disruption of the AAV space, though it...
2:27 PM, Feb 02, 2018  |  BioCentury | Finance

Building momentum

Avrobio Inc. parlayed positive clinical data and an aggressive in-licensing strategy into a $60 million series B round that will fund early clinical development of three long-acting lysosomal storage disease candidates. Cormorant Asset Management and Surveyor...
2:23 PM, Feb 02, 2018  |  BioCentury | Product Development

Local advantage

Theravance Biopharma Inc. is reaching a key inflection point for the first candidate to emerge from its program to develop me-better immunology therapies that act locally and avoid systemic side effects. The company will report...
2:07 PM, Feb 02, 2018  |  BioCentury | Finance

Private ambition

BB Biotech AG (SIX:BION; Xetra:BBZA) made a rare private investment in Moderna Therapeutics Inc.’s $500 million series G round and wants to see clinical proof-of-concept data from at least one rare liver disease asset before...
2:07 PM, Feb 02, 2018  |  BioCentury | Finance

Celgene sticks with the combo

While the market showed relative indifference to the appointment of CEO Mark Alles to the additional role of chairman of Celgene Corp. (NASDAQ:CELG), it goes against the trend among the big biotechs. On Jan. 29 Celgene...
1:46 PM, Feb 02, 2018  |  BioCentury | Finance

Follow-on frenzy

Four bankers who spoke with BioCentury said January’s biotech follow-on market has benefited from positive investor sentiment and an influx of generalists driven by a combination of tax reform and increased M&A. Biotechs raised $4 billion...
9:42 PM, Jan 26, 2018  |  BioCentury | Strategy

Jump-starting growth

Celgene Corp.’s two deals this month -- including its largest ever acquisition, of Juno Therapeutics Inc. -- will help fill in the holes left by late-stage failures and commercial disappointments of candidates that were intended...
6:03 PM, Jan 26, 2018  |  BioCentury | Finance

All together now

Promising proof-of-concept data from BioCryst Pharmaceuticals Inc. and a management team from Idera Pharmaceuticals Inc. with the requisite market know-how proved the right combination for a merger of two of the industry’s longest-standing independent small...
5:40 PM, Jan 26, 2018  |  BioCentury | Strategy

Growing up Genzyme

The proposed acquisition of Bioverativ Inc. ticks multiple boxes on Sanofi’s to-do list for transforming itself into a top tier pharma, and solidifies the position of its Genzyme unit as the pharma’s growth engine. Olivier Brandicourt...
5:10 PM, Jan 26, 2018  |  BioCentury | Finance

Earnings on deck

Earnings on deck At least 15 profitable biotechs and pharmas are slated to report earnings this week. (A) Fiscal 3Q; (B) Nine-month EPS; (C) 12-month EPS CompanyDatePre/post mkt4Q17 EPS est4Q16 EPSExpected chgPfizer Inc. (NYSE:PFE)1/30During$0.56$0.4719%Illumina Inc. (NASDAQ:ILMN)1/30Post$1.21$0.8542%Sumitomo Dainippon...